Clinical Targeted Next-Generation Panel Sequencing Reveals MYC Amplification Is a Poor Prognostic Factor in Osteosarcoma.

Amanda E MarinoffLiam F Spurr Christina FongYvonne Y LiSuzanne J ForrestAbigail WardDuong DoanLaura B Corson Audrey Mauguen Navin R Pinto Luke D Maese Susan I Colace Margaret E MacyAeRang KimAmit J Sabnis Mark A Applebaum Theodore W Laetsch Julia L Glade Bender Daniel A WeiserMegan AndersonBrian D Crompton Paul A Meyers Ahmet Zehir Laura MacconaillNeal LindemanJonathan Andrew Nowak Marc Ladanyi Alanna J Church Andrew D Cherniak Neerav N Shukla Katherine A Janeway

Published in: JCO precision oncology (2023)

amplification, detected with clinical targeted next-generation sequencing panel tests, is associated with poorer outcomes in two independent cohorts.

Keyphrases